Evaxion Biotech A/S
EVAX
Rank in Stocks
#26982
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Share Price
$2.75
Last synced: 2026-11-09
Market Cap
$17.37M
Change (1 day)
-8.33%
Change (1 year)
-54.47%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Evaxion Biotech A/S (EVAX)
Category
Healthcare
Operating Margin for Evaxion Biotech A/S (EVAX)
Operating Margin as of November 2026 TTM: -115.98%
According to Evaxion Biotech A/S's latest financial reports, its current operating margin (TTM) is -115.98%. At the end of 2025 the company had an operating margin of -122.66%.
Operating Margin history for Evaxion Biotech A/S from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -115.98% | -5.45% |
| 2025 | -122.66% | -72.16% |
| 2024 | -440.55% | -98.55% |
| 2023 | -30,406.85% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.33% |
US
|
|
| -149.01% | -98.72% |
US
|
|
| 25.57% | -100.22% |
AU
|
|
| 31.23% | -100.27% |
BE
|
|
| 29.35% | -100.25% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Evaxion Biotech A/S's operating margin
What is Evaxion Biotech A/S's operating margin?
Evaxion Biotech A/S's operating margin is -115.98%, as of Nov 2026.
What was Evaxion Biotech A/S's operating margin in 2025?
In 2025, Evaxion Biotech A/S's operating margin was -122.66%, compared with -440.55% in 2024.
How has Evaxion Biotech A/S's operating margin changed since 2020?
From 2020 to 2025, Evaxion Biotech A/S's operating margin was highest in 2022 (0.00%) and lowest in 2023 (-30,406.85%).
How does Evaxion Biotech A/S's operating margin compare with similar companies?
Evaxion Biotech A/S's operating margin (-115.98%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.